

The demonstration of expressed microsatellite proteins (MSH₂) on colorectal carcinoma tissue

¹Chukwunalu Igbudu Umoke, ²Kenneth Tochukwu Onwe, ³Paul Orijeji, ¹Chukwudum Collins Umoke and ⁴Emmanuel Ifeanyi Obeagu

¹Department of Human Anatomy, Alex Ekwueme Federal University, Ndufu Alike, Ikwo, Ebonyi State, Nigeria.

²Department of Anatomic Pathology, Federal Medical Center, Abuja, Nigeria.

³Department of Vocational and Technical Education, Alex Ekwueme Federal University, Ndufu Alike, Ikwo, Ebonyi State, Nigeria.

⁴Department of Medical Laboratory Science, Kampala International University, Uganda.

ABSTRACT

This study was carried out to evaluate the expression of microsatellite protein (MSH₂) on colorectal cancer specimen. A total of 32 tissue specimens of colorectal carcinoma from Meena Histopathological and Pap smear Screening Centre Jos and Federal staff Hospital Abuja were reviewed and analyzed Immunohistochemically for the expression of MSH₂ protein with colorectal cancer samples. Nineteen (59.3%) of colorectal cancer revealed 17(53.1%) showed negative reaction to MSH₂ protein. Five (35.7%) of moderate differentiated adenocarcinoma showed stage II of colorectal cancer with MSH₂ protein and 1(7.1%) showed stage III of colorectal cancer with MSH₂ protein. Four (40%) of well differentiated adenocarcinoma revealed stage II of colorectal cancer while 2(20%) showed stage III of colorectal cancer with MSH₂ protein. In one (12.5%) of poor differentiated adenocarcinoma were stage II of colorectal cancer with MSH₂ protein and 2(25%) showed stage III of colorectal cancer with MSH₂ protein.

Keywords: microsatellite proteins, msh₂, colorectal carcinoma

INTRODUCTION

Colorectal cancer are those growths that principally originate on the colon, rectum and appendix, and are capable of spreading to other parts of the body [1]. This occurs due to mutations along the Wnt signaling pathway. Adenomatous polyposis coli gene (APC) is the common gene that is affected in colorectal cancer. Adenomatous polyposis coli gene produces adenomatous polyposis coli protein that regulates the activity of β -catenin protein in the body [2]. β -catenin if not controlled by APC protein will bind to DNA and activate more proteins that will lead to the production of many abnormal cells [2]. There are some other mutations that cause cells to grow abnormally and they include- those of TP⁵³ gene that produce P⁵³ protein which monitors division of cell and cells that have defects in Wnt pathway [3]. Most times, these genes are not mutated, but other protective proteins like BAX and SMAC are not activated. Some genes such as

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

RAS, RAP and P19K which help during normal cell division are over expressed in colorectal cancer due to mutations [4]. Globally more than one million people are presented with colorectal cancer yearly [5] and this resulted to 715,000 deaths in 2010, almost a double of 490,000 in 1990 [6]. In the year 2008, colorectal cancer was rated second most common cancer among women and third most common type of among men globally [7]. Colorectal cancer is the fourth most common cause of cancer deaths after cancer of the lungs, cancer of the stomach and cancer of the liver [8]. Colorectal cancer is more prevalent in developed countries than in the developing ones. However, adequate statistics are not available in developing countries like Nigeria, because not all cancer-related deaths are documented and reported.

MATERIALS AND METHODS

Ethical Clearance

Before conducting the research, ethical clearance was obtained from National Hospital ethical committee. Ethical consideration were applied during sampling and analysis stages of the project.

Methods

All the methods used in this work were done following the protocols as prescribed by immunohistochemical staining procedures.

Sample Collection

The record books of histopathology laboratories of Meena Histopathology Laboratory and Pap Smear Screening Centre Jos and those of Federal Staff Hospital Abuja, were reviewed and thirty two (32) tissue blocks, (20 and 12 samples respectively) diagnosed of colorectal carcinoma were selected and reprocessed, sectioned on microtome and collected on microscopic slides and stained with haematoxylin and eosin and MLH₁ /MSH₂ proteins.

Immunohistochemical Staining Method

Avidin-biotin complex method

A cut sections of about 2 microns thick each from the 32 tissue blocks were made. The sections were fixed in hot plate for one hour and further dewaxed in xylene and then taken through descending grades of alcohols (100%, 90% and 70%) to hydrate it and finally to water. The sections were treated in antigen retrieval buffer (citrate acid P^H 6.0) and boiled in pressure cooker at 100^oC for 25 minutes. The sections were dipped into deionized water and blocked with endogenous peroxidase using peroxidase block for 15 minutes, and rinsed in phosphate buffer saline and block with protein using protein block (Avidin) for 15 minutes. The sections were rinsed in phosphate buffer saline and blocked with biotin using biotin block for 15 minutes and rinsed in phosphate buffer saline, and incubated with MLH₁ and MSH₂ protein (primary antibody) for 60 minutes. The sections were rinsed in phosphate buffer saline and incubated with post primary antibody for 15 minutes. After rinsing the sections with phosphate buffer saline, the sections were incubated with polymer for 15 minutes and rinsed in phosphate buffer saline, and incubated with diaminobenzidine (DAB) for 4 minutes and the colour changes were observed. The sections were rinsed in deionized water and counter-stained with haematoxylin for 2 minutes, Blued in scotch's tap water, dehydrated in ascending grades of alcohol and allowed to dry. DPX was used to mount the section and covered with coverslip and examined microscopically. The immunohistochemical method demonstrated showed different levels of positive reaction in the nucleus of the cancer cells, which corresponds to the various levels of brown colour.

Haematoxylin and Eosin Staining Method

Cut sections of 2 micron thick from the tissue blocks were made, dewaxed and taken through descending grades of alcohol. The sections were stained with haematoxylin for 15 minutes and rinsed in water. The sections were further differentiated in 1% acid alcohol, rinsed in water and blued in tap water for 5 minutes. The sections were stained with eosin for 2 minutes and rinsed in water, dehydrated by passing through 90% alcohol for 15 seconds, absolute I for 15 seconds and absolute II for 15 seconds. The sections were cleared in xylene, mounted with DPX and examined microscopically.

Histopathologic Evaluation

Posh formular was used in grading the work according to World Health Organization criteria [9].

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The formula is stated thus:
 $\frac{0}{3} + \frac{0}{5} = \frac{0}{8} = \text{Negative control}$

$$\frac{1}{3} + \frac{0}{5} = \frac{1}{8}$$

$$\frac{1}{3} + \frac{1}{5} = \frac{2}{8}$$

$$\frac{2}{3} + \frac{1}{5} = \frac{3}{8}$$


$$\frac{1}{3} + \frac{2}{5} = \frac{4}{8}$$

$$\frac{2}{3} + \frac{3}{5} = \frac{5}{8}$$

$$\frac{3}{3} + \frac{3}{5} = \frac{6}{8}$$

$$\frac{3}{3} + \frac{4}{5} = \frac{7}{8}$$

$$\frac{3}{3} + \frac{5}{5} = \frac{8}{8}$$



Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig 1: Showing Stage III of Poor Differentiated Adenocarcinoma with MSH₂ protein (Moderate Positive) by x10 magnification.

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig 2: Showing Stage II of Well differentiated adenocarcinoma with MSH₂ (Mild Positive) by x 10 magnification.

RESULTS

Table 1: Expression of MSH₂ protein in colorectal cancer

Haematoxylin and eosin features	Number of tissue sections	Number positive	Percentage positive (%)	Number negative	Percentage negative (%)
Moderate differentiated adenocarcinoma (MDA)	14	6	42.8	8	57.1
Well differentiated adenocarcinoma (WDA)	10	6	60	4	40
Poor differentiated adenocarcinoma (PDA)	8	3	37.5	5	62.5
Total	32	15	46.8	17	53.1%

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DISCUSSION

Out of 32 tissue specimens analyzed with immunohistochemical method 15 (46.8%) specimen showed positive expression to MSH₂ protein and 17(53.1%) specimen showed negative expression to MSH₂ protein. This is in agreement with the work of Vasen *et al.* [10-11] which reported that Ninety percent (90%) of hereditary non-polyposis colorectal cancer showed mutation of MLH₁ and MSH₂ protein.

This support the work of Aaltonen *et al.* [12] and Fishel *et al.* [13] which reported that 40%-60% of MSH₂ protein mutation associate with the increase risk that lead to the formation of colorectal cancer and 50%-80% of MLH₁ protein mutation associate with the increase risk that lead to formation of colorectal cancer. Three stages of colorectal cancer were classified in this work using posh formular according to world health organization criteria [9]. While the age group of 51-55 years of 3 specimens showed stage II of colorectal cancer with MSH₂ protein, stage III of colorectal cancer with MSH₂.

CONCLUSION

The results from this study shows that the immunohistochemical test for MSH₂ protein showed a rapid and reliable method for the detection of the larger majority of mismatch repair defect in colorectal carcinoma. Also the results showed that MSH₂ protein expression is useful in grading stages of colorectal cancers from stage II, III and IV in a patient.

REFERENCES

1. National Cancer Institute. Colorectal Cancer Prevention. 2014.
2. Behrens J. The role of the wnt signalling pathway in colorectal tumorigenesis, biochemical society transaction, 2005; 33 part 4.
3. Markowitz SD. Aspirin and colon cancer— targeting prevention. *National England Journal of Medicine*, 2007; 356:2195-2198.
4. Dimitriadis A, Vincan E, Mohammed IM, Roczo N, Philips WA, Baidur-Hudson S. Expression of wnt genes in human colon cancers. *Cancer letters*, 2001; **166** (2): 185-191.
5. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. *Lancet*, 2010; 375 (9719): 1030-1047.
6. Lozano R. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". *Lancet*, 2012; **380** (9859): 2095-128.
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: *Cancer Lin*, 2011; **61**: 69-90.
8. WHO. Cancer. World Health Organization. 2011.
9. Jass JR, Sobin LH. Histological classification of tumours. *Histological typing of intestinal tumour* Berlin, Germany, Springer-verlag. (ed 2). 1989.
10. Vasen HF, Moslem G, Alonso A, Bernstein L Bertario L, Blanco L, Burn J, Capella, G, Engel C, Frayling I. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *Journal of Medicine Genetics*, 2007; 44:353-362.
11. Umoke CI, Umoke CC, Oriji P, Madukwe J, Bunu UO, Obeagu EI. The demonstration of expressed microsatellite protein (MLH1) on colorectal carcinoma tissue. *Int. J. Adv. Res. Biol. Sci.* 2023;10(3):144-50.
12. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. *Cancer Reserve*, 2008; 54: 1645-1648.
13. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*, 1993; **93**, 75: 1027-1038.

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chukwunalu Igbudu Umoke, Kenneth Tochukwu Onwe, Paul Orijeji, Chukwudum Collins Umoke and Emmanuel Ifeanyi Obeagu (2023). The demonstration of expressed microsatellite proteins (MSH_L) on colorectal carcinoma tissue. *NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)* 3(2):6-12.

Umoke *et al*

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.